Showing 1 – 20 of 61
SORT: Best Match Most Recent Oldest
VIEW: Basic | Expanded
  • Original Contribution April 10, 2013

    Mingzhao Xing, MD, PhD; Ali S. Alzahrani, MD; Kathryn A. Carson, ScM; David Viola, MD; Rossella Elisei, MD; Bela Bendlova, PhD; Linwah Yip, MD; Caterina Mian, MD; Federica Vianello, MD; R. Michael Tuttle, MD; Eyal Robenshtok, MD; James A. Fagin, MD; Efisio Puxeddu, MD, PhD; Laura Fugazzola, MD; Agnieszka Czarniecka, MD; Barbara Jarzab, MD, PhD; Christine J. O’Neill, MBBS(Hons), MS; Mark S. Sywak, MD; Alfred K. Lam, MD, PhD; Garcilaso Riesco-Eizaguirre, MD, PhD; Pilar Santisteban, PhD; Hirotaka Nakayama, MD; Ralph P. Tufano, MD; Sara I. Pai, M.D, PhD; Martha A. Zeiger, MD; William H. Westra, MD; Douglas P. Clark, MD; Roderick Clifton-Bligh, PhD; David Sidransky, MD; Paul W. Ladenson, MD; Vlasta Sykorova, PhD
    TOPICS: mortality, neoplasms, thyroid carcinoma, papillary, metastasis, distant, braf gene, braf v600e mutation

    JAMA. 2013; 309(14):1493-1501. doi: 10.1001/jama.2013.3190

    Includes: Supplemental Content
  • Other Articles February 11, 1961

    A. H. Letton, M.D.; John P. Wilson, M.D.

    JAMA. 1961; 175(6):527-527. doi: 10.1001/jama.1961.03040060100030

  • Other Articles January 05, 1963

    Richard D. Liechty, MD; Robert E. Hodges, MD; Janice Burket

    JAMA. 1963; 183(1):30-32. doi: 10.1001/jama.1963.63700010003014a

  • Original Investigation April 19, 2016

    Antoni Ribas, MD, PhD; Omid Hamid, MD; Adil Daud, MD; F. Stephen Hodi, MD; Jedd D. Wolchok, MD, PhD; Richard Kefford, MD, PhD; Anthony M. Joshua, MBBS, PhD; Amita Patnaik, MD; Wen-Jen Hwu, MD, PhD; Jeffrey S. Weber, MD, PhD; Tara C. Gangadhar, MD; Peter Hersey, MD, PhD; Roxana Dronca, MD; Richard W. Joseph, MD; Hassane Zarour, MD; Bartosz Chmielowski, MD, PhD; Donald P. Lawrence, MD; Alain Algazi, MD; Naiyer A. Rizvi, MD; Brianna Hoffner, BA, RN, MSN; Christine Mateus, MD; Kevin Gergich, MA; Jill A. Lindia, MS; Maxine Giannotti, BS; Xiaoyun Nicole Li, PhD; Scot Ebbinghaus, MD; S. Peter Kang, MD; Caroline Robert, MD, PhD
    TOPICS: melanoma, neoplasms, toxic effect, pembrolizumab, immune checkpoint inhibitors

    JAMA. 2016; 315(15):1600-1609. doi: 10.1001/jama.2016.4059

    Includes: Multimedia, Supplemental Content